A Multi-Centre, Randomised, Double-Blind, Cross-Over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) 320/9microg One Inhalation Twice Daily Compared With Placebo and Oxis [formoterol] 9microg One Inhalation Twice Daily in Patients With Severe COPD [chronic obstructive pulmonary disease]

Trial Profile

A Multi-Centre, Randomised, Double-Blind, Cross-Over Design Study to Evaluate Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) 320/9microg One Inhalation Twice Daily Compared With Placebo and Oxis [formoterol] 9microg One Inhalation Twice Daily in Patients With Severe COPD [chronic obstructive pulmonary disease]

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs Budesonide/formoterol; Formoterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 05 Aug 2010 Primary endpoint results (n=111) published in Respiratory Medicine
    • 05 Oct 2008 Actual patient number (137) added as reported by ClinicalTrials.gov.
    • 05 Oct 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top